Exelixis
EXEL
#1646
Rank
HK$77.41 B
Marketcap
HK$280.92
Share price
0.11%
Change (1 day)
56.87%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): HK$2.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$2.20. In 2022 the company made an earnings per share (EPS) of HK$4.42 a decrease over its 2021 EPS that were of HK$5.74.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$2.22-49.73%
2022HK$4.42-22.97%
2021HK$5.74100%
2020HK$2.87-65.09%
2019HK$8.23-53.91%
2018HK$17.85333.96%
2017HK$4.11-260.61%
2016-HK$2.56-58.75%
2015-HK$6.21-42.45%
2014-HK$10.795.3%
2013-HK$10.2543.48%
2012-HK$7.14-264.29%
2011HK$4.35-165.88%
2010-HK$6.60-32.54%
2009-HK$9.78-17.65%
2008-HK$11.8875.86%
2007-HK$6.75-25.64%
2006-HK$9.088.33%
2005-HK$8.38-42.86%
2004-HK$14.6730.34%
2003-HK$11.26-5.23%
2002-HK$11.88-0.65%
2001-HK$11.95-51.88%
2000-HK$24.84

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
HK$27.17 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$24.69 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
HK$14.14 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$30.82 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.84 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.33 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$14.44 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$77.62-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$6.52-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA